Multiple sclerosis is the most common neurological disorder of the young adult causing major disabilities, at least in the countries of Europe and North America. Even more, the Multiple Sclerosis medications may cause a potentially deadly side effect, namely Progressive Multifocal Leukoencephalopathy (PML).
There is no cure for Multiple Sclerosis, yet
Despite the enormous amount of research over the last 10 to 15 years trying to elucidate the etiology of Multiple Sclerosis, the current medical knowledge is still far from explaining a cause of this disease.
Unfortunately, this means there is not yet an etiological treatment that will cause the cure of the disorder.
However, the knowledge of the complex chain of pathogenic events, which is constantly being developed, could underpin the development of therapeutic possibilities which under certain conditions (evolutionary form, the moment of the introduction of therapy) increase the chances in the majority of the patients suffering from Multiple Sclerosis to reduce the disease’s characteristics.
Therefore, usual treatments change the natural evolution of the disease in the terms of increasing the distance between relapses, decreasing the duration and the severity of the stroke, and reducing the accumulation of brain damage.
The most common medication against Multiple Sclerosis may produce a lethal side effect
Natalizumab is a monoclonal antibody used in the treatment of multiple sclerosis in its very active relapsing-remitting form.
However, in clinical trials, approximately 9% of natalizumab-treated patients developed anti-drug antibodies, and their presence resulted in decreased natalizumab serum levels, reduced responses to the treatment, and increased side effects.
In the recent years, many studies revealed that Natalizumab medication for Multiple Sclerosis may cause a potentially lethal side effect called Progressive Multifocal Leukoencephalopathy (PML), which is a rare brain infection that could be deadly.
A new study conducted by the NYU Langone Health experts in Multiple Sclerosis concluded that the probability of developing PML in patients treated with Natalizumab reduces significantly when the medication dose is increased from 300 mg a day for 4 weeks to 300 mg a day for 5 to 12 weeks.